Considering patient age when treating multiple sclerosis across the adult lifespan

ABSTRACT Introduction: The successful development of anti-inflammatory disease-modifying treatments (DMT) significantly improved disease outcomes and longevity of persons with multiple sclerosis (pwMS). However, the shift toward an elderly MS population has resulted with new concerns regarding DMT efficacy and safety. Areas covered: This review summarizes the evidence of an age-based decrease in the efficacy of MS DMTs and increase in pharmacovigilance concerns. The age effects on pathophysiological MS processes, immunosenescence and its relevance to DMT selection or discontinuation are also reviewed. Lastly, the authors discuss the influence of age-associated comorbidities on DMT initiation and drug-induced events. Expert opinion: There is an age discrepancy between pwMS included in regulatory drug trials and an aging real-world MS population. Most trials demonstrate significantly diminished anti-inflammatory efficacy in patients older than 40 years old. Older age is associated with a greater risk for adverse events including serious infections. Age-associated comorbidities influence the risk-benefit analysis and sometimes cause patients to discontinue DMTs. Instead of chronological age cutoffs, therefore, studies should aim at promoting biologically-based age biomarkers.

[1]  D. Ramasamy,et al.  Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. , 2020, Multiple sclerosis and related disorders.

[2]  R. Benedict,et al.  Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis. , 2020, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[3]  D. Arnold,et al.  Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial , 2020, The Lancet Neurology.

[4]  C. Gasperini,et al.  Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression , 2020, Multiple sclerosis.

[5]  N. Sicotte,et al.  Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society. , 2020, JAMA neurology.

[6]  J. Kuhle,et al.  Increasing cancer risk over calendar year in people with multiple sclerosis: a case–control study , 2020, Journal of Neurology.

[7]  D. Ramasamy,et al.  Late onset multiple sclerosis is associated with more severe ventricle expansion. , 2020, Multiple sclerosis and related disorders.

[8]  X. Montalban,et al.  Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. , 2020, Multiple sclerosis and related disorders.

[9]  C. Pozzilli,et al.  Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. , 2020, Brain : a journal of neurology.

[10]  L. Blizzard,et al.  Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis , 2020, Journal of Neurology.

[11]  X. Montalban,et al.  Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy , 2020, Multiple sclerosis.

[12]  R. Zivadinov,et al.  Long-term drug treatment in multiple sclerosis: safety success and concerns , 2020, Expert opinion on drug safety.

[13]  M. S. Cepeda,et al.  Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States , 2020, BMC Neurology.

[14]  R. Marrie,et al.  Comorbidity is associated with disease activity in MS , 2020, Neurology.

[15]  D. Ramasamy,et al.  Sex‐Specific Differences in Life Span Brain Volumes in Multiple Sclerosis , 2020, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[16]  O. Ciccarelli,et al.  Longitudinal Assessment of Multiple Sclerosis with the Brain‐Age Paradigm , 2020, Annals of neurology.

[17]  S. Ocklenburg,et al.  Association between shorter leukocyte telomeres and multiple sclerosis , 2020, Journal of Neuroimmunology.

[18]  T. Olsson,et al.  Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. , 2020, JAMA neurology.

[19]  M. Ramanathan,et al.  Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective , 2020, Vaccines.

[20]  C. Jack,et al.  Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis , 2020, Annals of neurology.

[21]  M. Freedman,et al.  Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study , 2020, CNS Drugs.

[22]  M. Wallin,et al.  Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials , 2020, Therapeutic advances in neurological disorders.

[23]  H. Wiendl,et al.  Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[24]  R. Henry,et al.  Telomere Length Is Associated with Disability Progression in Multiple Sclerosis , 2019, Annals of neurology.

[25]  L. Wilkins.  The prevalence of MS in the United States , 2019, Neurology.

[26]  E. Celius,et al.  Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study , 2019, Multiple sclerosis.

[27]  J. Sejvar,et al.  Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis , 2019, Neurology.

[28]  D. Ramasamy,et al.  Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis , 2019, Human brain mapping.

[29]  Jeffrey A. Cohen,et al.  Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies , 2019, Multiple sclerosis.

[30]  J. Hippisley-Cox,et al.  Anticholinergic Drug Exposure and the Risk of Dementia , 2019, JAMA internal medicine.

[31]  M. Zaffaroni,et al.  Impact of natural menopause on multiple sclerosis: a multicentre study , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[32]  G. Fink,et al.  Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis , 2019, Current opinion in neurology.

[33]  M. Ramanathan,et al.  Epidemiology and treatment of multiple sclerosis in elderly populations , 2019, Nature Reviews Neurology.

[34]  R. Desai,et al.  Thirty-day readmissions in multiple sclerosis: An age and gender-based US national retrospective analysis. , 2019, Multiple sclerosis and related disorders.

[35]  M. Bottai,et al.  Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden. , 2019, JAMA neurology.

[36]  L. Wilkins.  Erratum: Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist. , 2019, Neurology. Clinical practice.

[37]  M. Ramanathan,et al.  Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. , 2019, Neurodegenerative disease management.

[38]  D. Ramasamy,et al.  Aging and Brain Atrophy in Multiple Sclerosis , 2019, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[39]  R. Benedict,et al.  Cognitive Profiles of Aging in Multiple Sclerosis , 2019, Front. Aging Neurosci..

[40]  Devon S. Conway,et al.  Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60. , 2019, Multiple sclerosis and related disorders.

[41]  Knut K. Kolskår,et al.  Cross-Sectional and Longitudinal MRI Brain Scans Reveal Accelerated Brain Aging in Multiple Sclerosis , 2019, Front. Neurol..

[42]  E. D’Amico,et al.  Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort , 2019, Front. Neurol..

[43]  Devon S. Conway,et al.  Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60 , 2019, Multiple sclerosis.

[44]  P. Robson,et al.  Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis , 2019, Proceedings of the National Academy of Sciences.

[45]  William T. Hu,et al.  CSF Cytokines in Aging, Multiple Sclerosis, and Dementia , 2019, Front. Immunol..

[46]  M. Ramanathan,et al.  The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging , 2019, Neural regeneration research.

[47]  X. Montalban,et al.  Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis , 2019, Journal of Neurology.

[48]  D. Ramasamy,et al.  A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS , 2019, American Journal of Neuroradiology.

[49]  J. Shay,et al.  Telomeres and telomerase: three decades of progress , 2019, Nature Reviews Genetics.

[50]  A. Chan,et al.  Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course , 2019, Therapeutic advances in neurological disorders.

[51]  A. Chan,et al.  Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age , 2019, Therapeutic advances in neurological disorders.

[52]  Hyon K. Choi,et al.  Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia , 2018, JAMA network open.

[53]  Moses Rodriguez,et al.  Age is a critical determinant in recovery from multiple sclerosis relapses , 2018, Multiple sclerosis.

[54]  M. Dalakas.  Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system , 2018, Therapeutic advances in neurological disorders.

[55]  H. Søndergaard,et al.  Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis , 2018, Multiple sclerosis.

[56]  L. Ferrucci,et al.  Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty , 2018, Nature Reviews Cardiology.

[57]  M. Sormani,et al.  Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study , 2018, Multiple sclerosis.

[58]  C. Franceschi,et al.  Inflammaging: a new immune–metabolic viewpoint for age-related diseases , 2018, Nature Reviews Endocrinology.

[59]  H. Wiendl,et al.  Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters , 2018, Multiple sclerosis.

[60]  Ludwig Kappos,et al.  Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study , 2018, The Lancet.

[61]  Yinshan Zhao,et al.  Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[62]  P. Sørensen,et al.  Smoking affects the interferon beta treatment response in multiple sclerosis , 2018, Neurology.

[63]  R. Greenblatt,et al.  Ovarian aging is associated with gray matter volume and disability in women with MS , 2018, Neurology.

[64]  S. Patten,et al.  Comorbidity increases the risk of relapse in multiple sclerosis , 2017, Neurology.

[65]  M. Sormani,et al.  Assessing association of comorbidities with treatment choice and persistence in MS , 2017, Neurology.

[66]  M. Greenwood,et al.  Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments , 2017, Front. Neurol..

[67]  J. Funk,et al.  A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers , 2017, British journal of clinical pharmacology.

[68]  F. Ladeira,et al.  The Influence of Menopause in Multiple Sclerosis Course: A Longitudinal Cohort Study , 2017, European Neurology.

[69]  Jeffrey A. Cohen,et al.  Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis , 2017, Neurotherapeutics.

[70]  S. Realmuto,et al.  Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study , 2017, BMC Neurology.

[71]  R. Capra,et al.  Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy , 2017, Journal of NeuroVirology.

[72]  M. Reindl,et al.  Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors , 2017, Multiple sclerosis.

[73]  M. Ramanathan,et al.  Ocrelizumab: a B-cell depleting therapy for multiple sclerosis , 2017, Expert opinion on biological therapy.

[74]  J. Berger,et al.  Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis , 2017, Current Neurology and Neuroscience Reports.

[75]  Simon Hametner,et al.  Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis , 2017, Brain : a journal of neurology.

[76]  Ruth Ann Marrie,et al.  Comorbidity in multiple sclerosis: implications for patient care , 2017, Nature Reviews Neurology.

[77]  J. Berger.  Classifying PML risk with disease modifying therapies. , 2017, Multiple sclerosis and related disorders.

[78]  B. Weinstock-Guttman,et al.  Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk , 2016, Journal of the Neurological Sciences.

[79]  J. Correale,et al.  Progressive multiple sclerosis: from pathogenic mechanisms to treatment. , 2016, Brain : a journal of neurology.

[80]  S. Montgomery,et al.  Risk of Premenopausal and Postmenopausal Breast Cancer among Multiple Sclerosis Patients , 2016, PloS one.

[81]  S. Krieger,et al.  The topographical model of multiple sclerosis , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[82]  Alyssa H. Zhu,et al.  Long‐term evolution of multiple sclerosis disability in the treatment era , 2016, Annals of neurology.

[83]  D. Arnold,et al.  Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis , 2016, Journal of Neurology.

[84]  J. Lechner-Scott,et al.  Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[85]  P. D. De Jager,et al.  Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort , 2016, Multiple sclerosis.

[86]  V. Yajnik,et al.  Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. , 2016, World journal of gastroenterology.

[87]  M. Filippi,et al.  Brain reserve against physical disability progression over 5 years in multiple sclerosis , 2016, Neurology.

[88]  J. Correale,et al.  Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. , 2016, JAMA neurology.

[89]  A. Vortmeyer,et al.  CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment , 2016, Neurology.

[90]  R. Marrie,et al.  Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis , 2016, Neurology.

[91]  M. Velarde,et al.  Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype. , 2016, Cell metabolism.

[92]  R. Elashoff,et al.  Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial , 2016, The Lancet Neurology.

[93]  B. Weinshenker,et al.  Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis , 2015, Neurology.

[94]  Gregory F. Wu,et al.  Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance , 2015, Multiple sclerosis journal - experimental, translational and clinical.

[95]  M. Sormani,et al.  Subgroups of multiple sclerosis patients with larger treatment benefits: a meta‐analysis of randomized trials , 2015, European journal of neurology.

[96]  Jeffrey A. Cohen,et al.  A systematic review of the incidence and prevalence of cancer in multiple sclerosis , 2015, Multiple sclerosis.

[97]  T. Maeda,et al.  Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening , 2015, Molecular and Cellular Biochemistry.

[98]  B. Weinshenker,et al.  Relapses and disability accumulation in progressive multiple sclerosis , 2015, Neurology.

[99]  T. Therneau,et al.  Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. , 2014, Mayo Clinic proceedings.

[100]  T. Olsson,et al.  Smokers run increased risk of developing anti-natalizumab antibodies , 2014, Multiple sclerosis.

[101]  Richard Nicholas,et al.  Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial , 2014, The Lancet.

[102]  J. Johnston,et al.  Btk Regulates Macrophage Polarization in Response to Lipopolysaccharide , 2014, PloS one.

[103]  M. Hutchinson,et al.  Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study , 2013, Journal of Neurology.

[104]  T. Olsson,et al.  Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers , 2013, PloS one.

[105]  B. Weinshenker,et al.  Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis , 2013, Multiple sclerosis.

[106]  L. Kappos,et al.  Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis , 2012, Multiple sclerosis.

[107]  F. Thaiss,et al.  Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. , 2012, Blood.

[108]  L. Kappos,et al.  Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study , 2012, The Lancet Neurology.

[109]  H. Lassmann,et al.  Explorer NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury , 2012 .

[110]  Pat Monaghan,et al.  Telomere length in early life predicts lifespan , 2012, Proceedings of the National Academy of Sciences.

[111]  M Daumer,et al.  Age and disability accumulation in multiple sclerosis , 2011, Neurology.

[112]  H. Lassmann,et al.  Oxidative damage in multiple sclerosis lesions , 2011, Brain : a journal of neurology.

[113]  P. Vermersch,et al.  Cancer and multiple sclerosis in the era of disease-modifying treatments , 2011, Journal of Neurology.

[114]  A. Handel,et al.  Multiple sclerosis and risk of cancer: a meta-analysis , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[115]  P. Sørensen,et al.  The changing demographic pattern of multiple sclerosis epidemiology , 2010, The Lancet Neurology.

[116]  Gilles Edan,et al.  Evidence for a two-stage disability progression in multiple sclerosis , 2010, Brain : a journal of neurology.

[117]  C. Wall,et al.  Age-related differences in integrin expression in peripheral blood lymphocytes , 2010, Immunity & Ageing.

[118]  J. Antel,et al.  Thymic involution and proliferative T-cell responses in multiple sclerosis , 2010, Journal of Neuroimmunology.

[119]  P. Vermersch,et al.  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[120]  Benjamin D Smith,et al.  Future of cancer incidence in the United States: burdens upon an aging, changing nation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  R. Marrie,et al.  Comorbidity delays diagnosis and increases disability at diagnosis in MS , 2009, Neurology.

[122]  L. Kappos,et al.  FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis , 2008, Neurology.

[123]  Yinshan Zhao,et al.  Relapses in multiple sclerosis are age- and time-dependent , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[124]  E. Blackburn,et al.  Telomere length is paternally inherited and is associated with parental lifespan , 2007, Proceedings of the National Academy of Sciences.

[125]  J. Sedivy,et al.  Cellular Senescence in Aging Primates , 2006, Science.

[126]  S. Vukusic,et al.  Natural history of multiple sclerosis: a unifying concept. , 2006, Brain : a journal of neurology.

[127]  B. Blomberg,et al.  Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. , 2005, Seminars in immunology.

[128]  G. Pawelec,et al.  Human immunosenescence: is it infectious? , 2005, Immunological reviews.

[129]  P. Linton,et al.  Age-related changes in lymphocyte development and function , 2004, Nature Immunology.

[130]  D. Arnold,et al.  Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study , 2013, Journal of Neurology.

[131]  L. Kappos,et al.  The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL , 2009, Journal of Neurology.

[132]  Edmus Coordinating.  Natural history of multiple sclerosis: A unifying concept , 2006 .

[133]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.